Brief: Nuvectis Pharma Announces FDA Clearance Of Ind For NXP800
21/06/2022 15:00
June 21 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA ANNOUNCES FDA CLEARANCE OF IND FOR NXP800
* NUVECTIS PHARMA INC - EXPECTS TO INITIATE PHASE 1B STUDY
IN
EARLY 2023 FOR NXP800
Source text for Eikon: ID:nGNXsYsp5
Further company coverage: NVCT.O
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin